Skip to main content

SNY

Stock
Health Care
Drug Manufacturers - General

Performance overview

SNY Price
Price Chart

Forward-looking statistics

Beta
0.67
Risk
23.54%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees90K
Market cap$122.4B

Fundamentals

Enterprise value$83.9B
Revenue$53.2B
Revenue per employee
Profit margin13.95%
Debt to equity23.01

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)$2.95
Dividend per share$8.85
Revenue per share$18.10
Avg trading volume (30 day)$108M
Avg trading volume (10 day)$110M
Put-call ratio

Macro factor sensitivity

Growth-0.6
Credit+2.1
Liquidity+0.2
Inflation-2.0
Commodities-0.5
Interest Rates-0.7

Valuation

Dividend yield18.34%
PEG Ratio9.78
Price to sales2.62
P/E Ratio9.78
Enterprise Value to Revenue1.58
Price to book0.78

Upcoming events

Next earnings dayJuly 31, 2025
Next dividend day
Ex. dividend dayMay 9, 2025

News

Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

Zacks Investment Research (June 25, 2025)
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury

A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.

CNBC (June 18, 2025)
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

CNBC Television (June 2, 2025)
Sanofi-Blueprint deal is a bullish signal about biotech M&A

The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi is set to buy Blueprint Medicines for over $9 billion, while Bristol-Myers Squibb plans to license a cancer drug from BioNTech.

Yahoo Finance (June 2, 2025)
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Sanofi SA SNY announced on Wednesday that it will invest at least $20 billion in the U.S. through 2030.

Benzinga (May 14, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free